Direct Answer
Edwards Lifesciences Corporation (NYSE: EW) is a medical device company focused on structural heart disease and hemodynamic monitoring. Headquartered in Irvine, California and founded in 1958, Edwards pioneered transcatheter aortic valve replacement (TAVR) with its SAPIEN valve platform, which replaces diseased aortic valves without open-heart surgery. Annual revenue of approximately $6 billion comes primarily from TAVR devices sold to hospitals globally. In 2024, Edwards spun off its critical care monitoring business to concentrate entirely on structural heart therapies. The company is expanding into transcatheter mitral and tricuspid repair and replacement as its next major growth category.
Company Snapshot
| Ticker | EW (NYSE) |
|---|---|
| Sector | Health Care / Medical Devices |
| Headquarters | Irvine, CA |
| Fiscal Year End | December 31 |
| SEC CIK | 0001099800 |
| Revenue (FY2024) | ~$6 billion |
| Key Products | SAPIEN TAVR valves, PASCAL mitral/tricuspid repair, EVOQUE replacement valves |
| Key Metrics | TAVR procedure volumes, TMTT adoption rate, gross margin, R&D as % of revenue, clinical trial milestones |
What Edwards Lifesciences Does
Edwards makes devices that cardiologists and cardiac surgeons implant to treat damaged or diseased heart valves without open-chest surgery. The TAVR procedure requires a specialized cardiac catheterization lab, a multi-disciplinary heart team, and ongoing clinical training -- all of which Ewards supports with dedicated field clinical specialists who are present at procedures to assist physicians. This clinical partnership model, combined with the high complexity of the procedures, creates deep hospital relationships and high switching costs. The transcatheter valve market is one of the fastest-growing segments in medical devices because it addresses a large unmet need (millions of patients with severe aortic stenosis) with a procedure that significantly improves quality of life and survival.
Frequently Asked Questions
How does Edwards Lifesciences make money?
Edwards Lifesciences makes money by selling transcatheter heart valves and hemodynamic monitoring products to hospitals and medical centers worldwide. Its transcatheter aortic valve replacement (TAVR) products, marketed under the SAPIEN brand, are the company's largest revenue driver and account for the majority of its roughly $6 billion in annual revenue. TAVR replaces diseased aortic valves through a catheter inserted in the femoral artery rather than requiring open-heart surgery. Edwards also sells transcatheter mitral and tricuspid therapies (TMTT) for other structural heart conditions and critical care monitoring systems that measure cardiac output and fluid responsiveness in ICU and surgical patients. Revenue is driven by procedure volumes, and each valve implant generates several thousand dollars of device revenue for Edwards.
What is TAVR and why was it transformative for heart disease treatment?
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a diseased aortic valve without open-heart surgery. Before TAVR, patients with severe aortic stenosis (a narrowing of the aortic valve that restricts blood flow from the heart) faced either surgical aortic valve replacement (SAVR), which requires cracking the chest and putting the patient on a heart-lung bypass machine, or palliative medical management if they were too frail for surgery. TAVR revolutionized treatment by allowing cardiologists to thread a collapsed replacement valve through the femoral artery in the groin, position it at the diseased valve, and expand it in place -- all without general anesthesia in many cases. This dramatically expanded the eligible patient population to include elderly, frail patients who could not tolerate surgery. Edwards Lifesciences received FDA approval for its SAPIEN valve in 2011, initially for inoperable patients, then progressively expanded to all risk categories including low-risk patients by 2019.
How does Edwards compete with Medtronic in transcatheter valves?
Edwards Lifesciences and Medtronic are the two dominant players in the transcatheter aortic valve replacement market globally, though Edwards has consistently held the leading share with its SAPIEN platform while Medtronic competes with its Evolut product line. Edwards pioneered the field and entered the market earlier, establishing clinical evidence and operator experience advantages. Both companies invest heavily in R&D and clinical trials to expand their valve systems into new anatomies (mitral, tricuspid) and new patient populations. The competitive dynamic in TAVR is characterized by clinical evidence battles -- major clinical trials (PARTNER, EVOLUT LOW RISK) directly compared outcomes between valves and influenced hospital purchasing. Edwards has also patent-protected key aspects of its SAPIEN valve design and has pursued IP litigation against Medtronic, resulting in settlements and cross-licensing agreements.
What growth opportunity does Edwards see beyond TAVR?
Edwards Lifesciences is pursuing transcatheter mitral and tricuspid therapies (TMTT) as its next major growth category. Mitral regurgitation (a leaky mitral valve) and tricuspid regurgitation affect large patient populations who currently lack good minimally invasive treatment options. Edwards' PASCAL device clips together the leaflets of a leaking mitral or tricuspid valve to reduce regurgitation without surgery, competing with Abbott's MitraClip (the current market leader in transcatheter mitral repair). Edwards is also developing transcatheter replacement valves for the mitral and tricuspid positions, which are anatomically more complex than the aortic position. TMTT represents a large addressable market that could eventually rival or exceed the TAVR market if clinical evidence supports broad adoption. The company spun off its critical care business in 2024 to focus entirely on structural heart devices.
What are Edwards Lifesciences' main risks?
Edwards Lifesciences' main risks include: competition from Medtronic, Abbott, and Boston Scientific in transcatheter heart therapies; TAVR market maturation as the highest-need patient population (high-surgical-risk patients) has already been converted and new patient growth depends on expanding into lower-risk and asymptomatic populations; clinical trial risk in TMTT, where negative trial results could significantly impair growth projections; procedure volume dependence on hospital staffing and capacity; reimbursement risk if CMS or international payers restrict TAVR indications or reduce payment rates; and concentration risk from heavy dependence on TAVR for most of its revenue. The 2024 critical care spin-off increases the company's revenue concentration in structural heart, amplifying both upside and downside from that single end market.